The present study was designed to investigate the effects of a phytoestrogenscontaining soy extract (SOYSELECT®, SSE) on the growth of estrogen-dependent (MCF-7) and estrogen-unresponsive (MDA-MB-231) human breast cancer xenografts in athymic mice. Results obtained provided evidence that MCF-7 tumors did not grow over the treatment period (five weeks) in ovariectomized females receiving 50 or 100 mg/kg/day SSE (oral route); administration of SSE also did not affect the estradiol-sustained growth of MCF-7 tumors in mice. Similarly, no effects on tumor growth were observed in SSEtreated mice bearing MDA-MB-231 xenografts. Data from pS2, progesterone receptor, and cyclin D1 mRNA expression in tumors showed that, although SSE was able to induce a moderate estrogenic effect in MCF-7 cells, it did not increase cellular proliferation and tumor growth, in our experimental conditions. Besides, when used in association with 17β-estradiol, it displayed antiestrogenic activity. The expression of other genes involved in tumor progression and angiogenesis, such as Thrombospondin 1, Trasforming Growth Factor β2, and Kallikrein 6 was also evaluated in tumor samples, results showing a decrease in mRNA expression upon SSE treatment. The effect of SSE on angiogenesis in vivo was also evaluated in the Matrigel plug assay; results obtained showed a striking antiangiogenic activity in mice receiving 100 mg/kg/day SSE, thereby confirming that this extract may interfere with angiogenesis. Collectively, these experimental data suggest that SSE could be not harmful for women with a history of or at high risk for breast cancer, at least for short treatment-periods; however, further studies are needed to thoroughly characterize the activity profile of the extract in this specific setting of patients.
INTRODUCTION
Worldwide, breast cancer is the most frequent cancer in women (1) . It has estimated that in the year 2002 there were more than one million new breast cancer cases all over the world, with the highest incidence rates observed in North America, Australia and North and Western Europe, and the lowest risk observed in Asia and Africa (1) . Differences in disease incidence have been largely attributed to environmental factors, and, in particular, it has been suggested that there could be a relationship between the eating habits of certain population and a reduced risk of developing this cancer. Asian diet is high in soy and several researchers have suggested that it may exert a protective action on the development of breast cancer, even though other diet features, such as a much lower content of saturated fats and a higher amount of fiber may have a role in reducing cancer risk. Although soy contains a number of putative biologically active compounds that may be relevant in breast cancer (2) , initial excitement over the hypothesized anticancer effects of this legume was based largely on the possibility that isoflavones might modulate estrogen action on breast tissue. Besides, consumption of soy-derived products has been encouraged for postmenopausal women as a natural alternative to hormone replacement therapy (HRT), with many women embracing soy products, isoflavone supplements, and foods to which isoflavones have been added. One group of women most in need of and who frequently use alternatives consists of breast cancer patients (3, 4) . Actually, the belief in dietary soy as an HRT alternative is generally stronger among women with a personal history of breast cancer, who are six times as likely to use dietary soy for the relief of menopause symptoms, as are other women (5) .
In contrast to correlations of soy consumption and breast cancer development, it has been suggested that exposure of pre-existing estrogen-dependent tumors to estrogenic effect of phytoestrogens may have a negative outcome, by stimulating growth. The 4 estrogenic effects of isoflavones observed in some experimental systems have recently led to considerable controversy among health professionals over the use of soy by breast cancer patients and to confusion among survivors (6) . Consequently, it is important to understand whether soy and/or isoflavones do pose a risk for breast cancer patients, and how the consumption of soy supplements may affect a pre-existing breast tumor.
The present study was designed to investigate the effects of a standardized soy extract on the growth of estrogen dependent (MCF-7) and estrogen-unresponsive (MDA-MB-231) human breast cancer xenografts in athymic mice. The modulation of specific processes governing tumor growth was evaluated as well, in an attempt to clarify the role played by soy products in breast cancer development. Notably, dose selection was based on previous results on this standardized extract, showing that administration of 100 mg/kg/day SSE to ovariectomized rats was effective in preventing experimental osteoporosis without stimulating proliferation in uterus and mammary gland (7, 8) .
Additionally, the treatment schedule was intended to reproduce isoflavones plasma levels comparable to those found in Japanese population on a traditional soy diet (9) , and to concentrations detected in a previous clinical trial in menopausal women receiving the tested extract (10) . For MCF-7 protocol, one week after arrival, a total of 60 mice were ovariectomized and allowed a week recovery. There were 6 experimental groups in the study, each consisting of 10 mice. Groups 2 and 3 received SSE at 50 and 100 mg/kg/day respectively, by oral gavage, five consecutive days per week, until the end of the study. Groups 4, 5 and 6 were implanted subcutaneously with 60-day release, 0.18 mg 17β-estradiol pellets (17β-E2) (Innovative Research of America, Sarasota, Fl) one week after ovariectomy; these pellets are designed to produce 80-100 pg/ml of serum estradiol (as indicated by the supplier). Mice in groups 5 and 6 also received SSE at the same doses and schedule treatment specified above; group 1 was used as a control and received the vehicle (i.e. sterile water p.o.). Treatments started one week after ovariectomy (i.e. the day before tumor inoculation). For the MDA-MB-231 protocol, a total of three experimental groups was used, each consisting of 10 mice; treatment (vehicle, SSE 50 or SSE 100 mg/kg/day) started the day of cell inoculation, at the same schedule treatment indicated above.
During the study, mice were checked daily for any adverse clinical reactions.
Tumor dimensions were measured with a caliper three times per week. Solid tumor weight was estimated from two dimensional measurements (mm): Tumor Weight = (Length x Width 2 )/2 (11). Body weight was also recorded three times per week; food intake was determined over several 24 h periods randomly throughout the study.
At the end of the study animals were sacrificed by carbon dioxide; uteri were rapidly removed, free of fat and weighted. All tumors were also removed, immediately placed in liquid nitrogen and stored at -80°C for subsequent analysis.
Angiogenesis Assay
The method described by Passaniti et al. (12) analyze the data by independently normalizing the two sets for GAPDH expression; the effects of SSE on gene expression was thus evaluated as SSE-treatment vs non-treatment ratio, separately in the two sets of data (i.e. with or without concomitant 17β-estradiol supplementation). Each analysis was repeated in triplicate, at least three times for each condition, and results were then averaged. Amplifications were carried out using the primers reported in Table 1 . To each primer, iQ SYBR Green Supermix (Bio-Rad) was used in a final volume of 25 µL, starting with a 3-minute template denaturation step at 95°C, followed by 40 cycles of 15 seconds at 95°C, and 1 minute at 60°C. Standard curves were generated using a serial dilution of the initial amount of control cDNA to determine the range of template concentrations, which showed a good linearity and efficiency for the different reactions. Melt curves of the reaction products were also generated to assess the specificity of the measured fluorescence. , where ∆Ct = Ct specific gene-Ct GAPDH and ∆(∆Ct) = ∆Ct specimen -∆Ct control. A fold change equal to 1 represents a sample with an expression level equal to the control cell line. This operation was done using the Excel spreadsheet RelQuant (Bio-Rad).
Statistics
All the data were analyzed for homogeneity of variance using Bartelett's test. If the group variance appeared homogenous, a parametric ANOVA was used, followed by 
RESULTS

Effect of SSE on the growth of MCF-7 in ovariectomized athymic female mice.
Ovariectomized athymic mice implanted with MCF-7 cells were divided into 6 treatment groups. As expected, MCF7 xenografts did not form proliferating tumors in ovariectomized hosts without estrogenic supplementation (negative controls) (Figure 1 ).
No growth was also observed in tumor-bearing mice treated with 50 or 100 mg/kg/day SSE A reduction in body weight gain was observed in all groups receiving 17β−estradiol when compared to negative control, though the statistical significance was achieved only for mice upon 17β−estradiol treatment alone (p<0.05) (Figure 2 ). In the absence of estrogenic supplementation, no effect on body weight was noticed in SSE-treated animals (low and high dose). A moderate reduction in food consumption was recorded in mice upon 17β−estradiol treatment alone when compared to vehicle controls (2.3 ± 0.2 vs 2.9 ± 0.7 g/mouse/day, respectively); food consumption in animal receiving 50 or 100 mg/kg/day SSE were 3.3 ± 0.1 and 3.2 ± 0.1 g/mouse/day, respectively; finally, values in groups receiving 17β-estradiol and SSE in association were 2.8 ± 0.2 and 2.9 ± 0.3, for the low and the high-dose group respectively.
Effect of SSE on the growth of MDA-MB-231 in athymic female mice. No differences in tumor growth were observed in animals receiving 50 or 100 mg/kg/day SSE when compared to vehicle controls ( Figure 3 ). In addition, test substance administration did not affect body weight of treated mice (data not shown).
Regulation of the mRNA expression by SSE treatment. To evaluate the ability of SSE to modulate mRNA expression of selected genes, we conducted quantitative RT-PCR analysis using mRNA isolated from MCF-7 tumors in negative controls, 100 mg/kg/day SSE-treated mice, positive controls (17β-estradiol) and mice receiving both treatments. Specifically, the following genes were evaluated: pS2, PR, cyclin D1, TGFB2
TSP and KLK6. Results obtained are shown in Figure 4 ; results are expressed as ratio of gene expression in SSE-treated over non-treated tumors, calculated after independent normalization in two different sets of data (i.e. with or without concomitant 17β-estradiol supplementation). In the absence of 17β−estradiol supplementation, the expression of pS2
and PR was significantly higher in SSE treated animals (p<0.05) compared to tumors from negative controls; conversely, in 17β−estradiol-supplemented tumors, SSE induced a statistically significant down-regulation of both genes (p<0.01 vs positive control). The expression of both Cyclin D1 and KLK6 was seen to be reduced by SSE without (p<0.05 and p<0.01 for Cyclin D1 and KLK6, respectively) or with 17β−estradiol supplementation (p<0.01 for both Cyclin D1 and KLK6), where the effect was more consistent in the degree of inhibition. On the other hand, a comparable modulation of TGFB2 expression in tumor samples was seen either in the presence or in the absence of 17β−estradiol (p<0.05 in both cases). Finally, 17β−estradiol-supplemented tumors from animals receiving SSE had significantly reduced levels of TSP expression with 17β−estradiol supplementation (p<0.01); in the absence of estrogenic supplementation, no significant changes were observed in SSE-treated tumors with respect to negative controls. 
DISCUSSION
The present study provided evidence that MCF-7 tumors did not grow over the study period in animals receiving 50 or 100 mg/kg/day of SSE, treatment also not affecting the 17β-estradiol-sustained growth of MCF-7. Similarly, no significant effects on tumor growth were observed in MDA-MB-231-bearing mice receiving both doses of SSE.
Conflicting data exist on the effects of soy-based products or pure phytoestrogens on breast tumor progression (reviewed in 6). In in vitro systems a biphasic effect of genistein on the growth of MCF-7 cells (i.e. stimulation at low and cytotoxicity at high concentrations) has been consistently observed (13) (14) (15) (16) , while, in in vivo studies, where high isoflavone plasma levels are not usually achieved, stimulatory effects on MCF-7 tumors have been generally reported (14, (17) (18) (19) . In particular, these latter studies from
Helferich's laboratory showed that dietary treatment with genistein/genistin dosedependently enhanced the growth of MCF-7 tumors in vivo, increasing cellular proliferation and inducing pS2 gene expression; it is worthy to note, however, that at low dietary genistein levels (i.e. ≤ 125 µg/g diet as aglycone) stimulation of tumor growth was not observed (17, 18) . Isoflavone dosages achieved in the present experiment were about 8 and 17 mg/kg rat/day, as glycoside (low-and high-dose group respectively); thus exposure levels were in the range of those found inactive in the above reported studies (if extrapolating dosages from dietary isoflavone concentrations) (17, 18) . In a later study by Collectively, our results are barely comparable to the above mentioned literature data when considering that different products with different schedule-treatment were tested, and it is generally accepted that the type, combination and doses of isoflavones are critical factors, likely modifiers of the different biological effects. In particular, as recently pointed out by Jeffery (22) , the evaluation of specific isoflavones alone (e.g., genistein), a combination of isoflavones, or isoflavones together with saponins or other components within soy protein, may provide very different patterns of activity and, in this context, the pharmaco-toxicological characterization of each single product appears essentially. Finally, also the duration of treatment could be crucial in determining the stimulatory effects of soy or pure genistein on estrogen-dependent breast cancer, as shown by previous preclinical studies (17, 20) and, in the light of this, the activity profile of SSE following prolonged administration deserves further investigations.
It is worth of note that the findings observed in the present study occurred at physiological plasma levels of phytoestrogens. In fact, a previous pilot study carried out in our laboratory showed that following administration of 50 and 100 mg/kg/day SSE to healthy athymic mice, plasma concentrations of total daidzein and genistein were as follows: total daidzein 1.1 ± 0.3 and 1.6 ± 0.7 µM, total genistein 0.8 ± 0.1 and 0.9 ± 0.2 µM (mean ± SD), for the low and the high-dose groups respectively (unpublished data).
Actually, these isoflavones blood levels are comparable to those found in Japanese women it is also possible that other components in the extract (e.g. soysaponins) could be responsible for or could contribute to the observed effects.
In order to better understand the specific molecular mechanisms by which the extract could exert its effect on MCF-7 tumors, a number of genes were identified and used to evaluate SSE (high dose) for its ability to produce estrogenic effects or to influence tumor suppression or progression. Collectively, our data showed that, in the absence of estrogenic supplementation, SSE was able to induce a moderate estrogenic effect in MCF- Factor β2 and Kallikrein 6 was found. In keeping with these findings, our results showed that SSE down-regulated the mRNA expression of both TSP and KLK6 (two genes recently showed to be estrogen-responsive) (27, 28) , with a more pronounced effect in 17β-estradiol-supplemented tumors; the effect on TGFB2 was instead independent on 17β- Fig.1 Effects of SSE on MCF7-tumor growth in ovariectomized athymic mice (mean ± SD, n=10 mice/group). One day before tumor inoculation, ovariectomized athymic mice were treated with 0 (negative control, NC), 50 or 100 mg/kg/day SSE, or implanted with 17β-estradiol pellet (17β-E2, 0.18 mg/pellet) and treated with 0 (positive control), 50 or 100 mg/kg/day SSE. Tumors were measured three times per week. **p<0.01 compared to negative control. at Pennsylvania State University on 
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